While meta-analyses suggest mixed results, some studies have reported that the rs2854116 polymorphism (T-455C) in the ApoC-III gene promoter may be associated with increased risk of MASLD, hypertriglyceridemia, and insulin resistance, particularly in Asian populations including South Asians, though the rs2854117 polymorphism (C-482T) shows less consistent associations. This evidence concerns the gene APOC3 and metabolic dysfunction-associated steatotic liver disease.